To sustain the high quality of research expected from this Partnership, strict planning and evaluation processeshave been implemented to monitor collaboration building, as well as all projects, programs and cores againstboth the Partnership's mission, goals and objectives, and the mission, goals and objectives of the U54mechanism itself, It is our intent to utilize Partnership funding for projects and programs to nurture theirdevelopment, but not to provide long-term support. As a part of building and sustaining excellence, all projectsand programs undergo a strenuous review by our internal and external committees (Table 38) and areexpected to (and must develop a plan to) apply for external funding from the NIH or an equivalent agency.These planning and evaluation processes are also instrumental in accurately assessing the Partnership'seffectiveness towards achieving its immediate (1-3 years) and intermediate (4-5 years) goals (See Section 1.5)of establishing a sustainable research infrastructure (e.g., key personnel recruitment, clinical accrual cores,tissue cores, assigned building space, and further defining programmatic approaches toward the developmentof the roadmap to obtain cancer center designation) at the UPRCCC. Not to mention, strategically, a strong planning and evaluation process is needed to aid the Partnership in achieving its long-term goal (post-U54funding) of regaining NCI-designation for the UPRCCC. Although regaining NCI-designation is not a directgoal within the scope of the U54 mechanism, as Pis, we believe that it is imperative for us to not justthink in terms of U54 specifics, but to pursue goals beyond the U54. For us, regaining NCI-designationis a positive step towards building a stronger national cancer program aimed at understanding thereasons behind cancer health disparities and their impact on the populations we serve.
| Yan, Fangrong; Zhu, Huihong; Liu, Junlin et al. (2018) Design and inference for 3-stage bioequivalence testing with serial sampling data. Pharm Stat 17:458-476 |
| Juan-Rivera, Maylein C; Martínez-Ferrer, Magaly (2018) Integrin Inhibitors in Prostate Cancer. Cancers (Basel) 10: |
| Gonzalez-Mercado, Velda J; Fridley, Brooke L; Saligan, Leorey N (2018) Sestrin family of genes and their role in cancer-related fatigue. Support Care Cancer 26:2071-2074 |
| Villar-Prados, Alejandro; Wu, Sherry Y; Court, Karem A et al. (2018) Predicting novel therapies and targets: Regulation of Notch3 by the bromodomain protein BRD4. Mol Cancer Ther : |
| Allen, Julie K; Armaiz-Pena, Guillermo N; Nagaraja, Archana S et al. (2018) Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. Cancer Res 78:3233-3242 |
| Marqués-Lespier, Juan M; Soto-Salgado, Marievelisse; González-Pons, María et al. (2018) Prevalence of Synchronous Oligopolyposis in Incident Colorectal Cancer: A Population-Based Study. P R Health Sci J 37:39-45 |
| Choi, Sangbum; Kang, Sangwook; Huang, Xuelin (2018) Smoothed quantile regression analysis of competing risks. Biom J 60:934-946 |
| González-Pons, María; Soto-Salgado, Marievelisse; Sevilla, Javier et al. (2018) Seroprevalence of Helicobacter pylori in Hispanics living in Puerto Rico: A population-based study. Helicobacter 23: |
| Monroig-Bosque, Paloma Del C; Shah, Maitri Y; Fu, Xiao et al. (2018) OncomiR-10b hijacks the small molecule inhibitor linifanib in human cancers. Sci Rep 8:13106 |
| Thapa, Bibek; Diaz-Diestra, Daysi; Santiago-Medina, Carlene et al. (2018) T1- and T2-weighted Magnetic Resonance Dual Contrast by Single Core Truncated Cubic Iron Oxide Nanoparticles with Abrupt Cellular Internalization and Immune Evasion. ACS Appl Bio Mater 1:79-89 |
Showing the most recent 10 out of 126 publications
